๐ฌDeep Research
JBIO โ Jade Biosciences Inc ยท catalysts, narrative & risks
Jade Biosciences Inc. (Nasdaq: JBIO) โ Point-in-Time Assessment (as of 2026-10-30)
Company Snapshot
Jade Biosciences is a clinical-stage biotechnology company developing monoclonal antibody therapies targeting the "upstream drivers" of autoimmune diseases, with a goal of patient-friendly, infrequent subcutaneous dosing [10]. Its lead programs are JADE101 (anti-APRIL, in IgA nephropathy/IgAN), JADE201 (anti-BAFF-R), and JADE301 (anti-IFN-ฮฒ, in dermatomyositis) [5], [9].
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ